# Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance

> **NCT07178457** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 84 (estimated)

## Conditions studied

- Cutaneous T Cell Lymphoma (CTCL)
- Brentuximab Vedotin

## Interventions

- **DRUG:** Brentuximab Vedotin (Bv)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07178457
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2032-11-01
- **Final completion:** 2032-11-01
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07178457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07178457, "Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07178457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*